Johnson & Johnson gets FDA warning on marketing

Aug 24, 2010 By LINDA A. JOHNSON , AP Business Writer

(AP) -- A Johnson & Johnson business that makes joint replacements has been warned by the Food and Drug Administration that it is illegally marketing two products.

The FDA notified Johnson & Johnson's DePuy Orthopaedics Inc. that it is selling one product that was never approved for sale and is selling another product for uses that have not been specifically approved.

In a letter to the company, the FDA wrote that DePuy is marketing its Corail Hip System for two unapproved uses, and promoting those uses in an online brochure.

The agency also stated that it never approved the TruMatch Personalized Solution System. It uses software and high-tech CT scanning technology to create a detailed, 3-D view of a patient's knee so a surgeon can properly position a knee implant.

The FDA has told DePuy, which is based in Warsaw, Ind., to stop selling the hip system for unapproved uses and to provide information that would be needed for the agency to approve the TruMatch system.

"The FDA will evaluate the information you submit and decide whether your product may be legally marketed," stated the letter.

In a statement, DePuy said it is "reviewing the letter to understand the FDA's concerns and will respond to their request for information."

The FDA's warning letter, addressed to DePuy President David Floyd, was posted on the agency's website on Tuesday. The letter is dated Aug. 19. It is signed by Timothy A. Ulatowski, director of the Office of Compliance in the FDA center that oversees medical devices.

It states that the Corail Hip System is approved for total hip replacement in patients with six specific types of damage to the hip. But a brochure on DePuy website claims the system can be used for treating two other conditions, according to the FDA.

On Monday, Johnson & Johnson issued its ninth product recall in a year, this one covering millions of 1 Day Acuvue TruEye contact lenses sold in Japan and two dozen other countries in Asia and Europe. The recall followed complaints from customers in Japan of an unusual stinging or pain when inserting the lenses. Johnson & Johnson's Vision Care Inc. business blamed the failure of manufacturing equipment that rinses off substances used in producing the lenses.

Johnson & Johnson already is under scrutiny by officials, Congress and federal prosecutors over eight previous U.S. recalls of nonprescription medicines since last September. Those included millions of bottles of Tylenol, other pain relievers and cold medicines for children and adults.

The recalls have involved problems ranging from bacterial contamination and a nauseating smell on containers to drugs that may have the wrong amount of active ingredient and liquid medicines that may contain tiny metal shavings.

In midday trading, Johnson & Johnson shares fell 78 cents to $58.08, while health-care stocks and the broader markets were all down.

Johnson & Johnson is based in New Brunswick, N.J.

Explore further: FDA approves AbbVie combo hepatitis C treatment

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Johnson&Johnson expands Tylenol recall

Jan 15, 2010

(AP) -- Johnson & Johnson expanded a recall of over-the-counter medications Friday, the second time it has done so in less than a month because of a moldy smell that has made users sick.

FDA found bacteria in lots for recalled Tylenol

May 04, 2010

(AP) -- Ingredients used by Johnson & Johnson in some of the 40 varieties of children's cold medicines recalled last Friday were contaminated with bacteria, according to a report by the Food and Drug Administration.

New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

FDA approves new breast cancer lab test

Jul 17, 2007

The U.S. Food and Drug Administration has approved the first molecular-based laboratory test for detecting whether breast cancer has metastasized.

J&J recalls infants', children's liquid Tylenol

Sep 25, 2009

(AP) -- Johnson & Johnson's McNeil unit said Thursday it is voluntarily recalling 57 lots of infants' and children's liquid Tylenol products because of possible bacterial contamination.

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.